FindTrial
Sign In

Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05572996
Enrollment
Unknown
Registered
2022-10-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema

Keywords

Inhaled Treprostinil, Tyvaso, EAP, Expanded Access, Early Access, Compassionate Use, Named Patient Program, NPP, PH-ILD

Brief summary

This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil. Availability will depend on territory elegibility.

Interventions

DRUGInhaled Treprostinil

Sponsors

Ferrer Internacional S.A.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. Patient consent 2. Males and females aged 18 years old or older 3. PH-ILD diagnosis: * Confirmed diagnosis of Group 3 PH by Right Heart Catheterization (RHC): \- mPAP \> 20 mmHg with PAWP ≤ 15 mmHg and PVR ≥ 2 WU and * Confirmed diagnosis of diffuse parenchymal lung disease based on imaging (any form of ILD or CPFE)

Exclusion criteria

1. Diagnosis of PAH or PH for reasons other than Group 3 PH-ILD 2. Use of concomitant PAH drugs contraindicated for PH-ILD (ambrisentan and riociguat) 3. Use of any concomitant investigational drug

Contacts

Primary ContactFerrer Medical Information
medinfo@ferrer.com+34 629 966 806

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026